

EPL Limited

29 July 2021

RESULT UPDATE

Sector: Packaging	Rating: BUY
CMP: Rs 266	Target Price: Rs 305

Stock Info

Sensex/Nifty	52,653 / 15,778
Bloomberg	ESEL IN
Equity shares (mn)	315.6
52-wk High/Low	Rs 318/ 199
Face value	Rs 2
M-Cap	Rs 76bn/ USD 1.1bn
3-m Avg volume	USD 0.7mn


Financial Snapshot (Rs mn)

Y/E Mar	FY21	FY22E	FY23E
Net sales	30,916	36,444	41,002
EBITDA	6,111	7,318	8,948
PAT	2,391	3,501	4,714
EPS (Rs)	7.6	11.1	14.9
PE (x)	32.5	21.4	16.0
P/B (x)	5.0	4.1	3.6
EV/EBITDA (x)	14.7	10.8	8.6
RoE (%)	15	20	24
RoCE (%)	16	21	28
D/E (x)	0.4	0.2	0.1
OPM (%)	19.8	20.1	21.8
Dividend yield (%)	1.5	2.3	3.1
Dividend payout (%)	49	49	49

Shareholding Pattern (%)

	Jun'21	Mar'21	Dec'20
Promoter	52.0	52.0	52.0
-Pledged	-	-	-
FII	14.6	14.9	13.8
DII	14.7	13.5	15.6
Others	18.7	19.6	18.7

Stock Performance (1-year)



Naushad Chaudhary
naushadchaudhary@systematixgroup.in
+91 22 6704 8036

Sequential margin recovery; outlook positive

EPL Limited's 1QFY22 result was slightly below our estimates with sales/EBITDA/APAT growth of 8%/-1%/30% YoY. Revenues were backed by strong growth in AMESA-India (+29% YoY, organic growth was in high-teens) and America (+9% YoY). EAP-China (+2% YoY) growth was lower while Europe declined (-10% YoY) on a high base (led by hand sanitizer tubes sales last year) and the Russia plant shutdown in 4QFY21. OPM was 18.1% vs. 19.8% YoY and 17.3% QoQ. The YoY decline in margin was due to 1) Columbia plant shutdown for 4 weeks (due to the national strike), 2) shutdown of one India plant for 3-4 weeks as one major oral care client halted production, 3) delay of 2-3 weeks in order dispatch from China due to logistics challenges and 4) a sharp rise in freight costs (4-5x in India-China, 1-2x in India-EU). Sequentially, OPM improved as RM prices softened (LDPE/HDPE prices are down 14%/10% from the 4QFY21 peak) and the company has re-negotiated prices with 90%+ clients (significant benefits expected in 2H). The in-house manufacturing of 'caps' should also boost margins going forward. The management maintained its guidance of double-digit volume growth over the next few years and a sequential improvement in OPM in FY22. We maintain our BUY rating on the stock with a target price of Rs 305 based on 20x FY23E EPS.

AMESA (India) – strong recovery in the beauty & cosmetic category: Sales/EBIT grew 29%/95% YoY and EBITM improved to 11% vs. 7.3% YoY. Adjusting for Creative Stylo Packs Pvt Ltd numbers, AMESA region growth was in the mid-teens (India growth was 17.3% YoY). Sales growth was led by a strong recovery in the beauty & cosmetics category, increased demand from pharmaceutical clients (new clients added), a new category (converting Henna cones into tubes) and wallet share gains. Margins improved due to higher personal care (PC) revenue share of 56.6% vs. 46% YoY. We expect sales CAGR of 12% and an average EBITM of 12.8% between FY21-23E led by a strong recovery in the B&C segment and increased demand from the pharmaceuticals category.

EAP (mainly China) – low growth on a high base; higher freight costs hit margins: Sales/EBIT grew 2%/-21% YoY and EBITM contracted to 16.7% vs. 21.7% YoY. Lower sales growth was due to a higher base (China witnessed a V-shaped recovery last year) and softness in demand for sanitizer tubes. Margins contracted due to higher freight costs and a decline in PC revenue share to 38.3% vs. 44.9% YoY. We expect sales CAGR of 12% and an average EBITM of 18.8% between FY21-23E led by an increased focus on fast-growing regional players and recovery in the oral care category (institutional sales) as travels are picking pace.

Americas – Labour-related challenges impacting growth; improvement in 2H: Sales/EBIT grew 9%/-23% YoY and EBITM contracted to 7.3% vs. 10.2% YoY. Lower sales growth was due to production shutdown at the Columbia plant for 4 weeks due to a national strike and continued labour challenges in the US (normalisation expected post Sep-2021). Margins were impacted due to lower capacity utilisation and a decline in PC sales share to 21.5% vs. 29.4% YoY. We expect sales CAGR of 12% and an average EBITM of 11.3% between FY21-23E given 1) labour shortage should resolve in 2H, 2) rise in travel tubes demand, 3) new client additions and 4) cross-selling of PC products to the existing oral care (OC) clients.

Europe – Russia plant shutdown & a higher base impact growth; recovery in 2H: Sales/EBIT declined 10%/45% YoY and EBITM declined to 5.5% vs. 9.9% YoY. Sales were impacted due to the shutdown of the non-profitable Russia plant in 4QFY21 and a higher base of sanitizer tubes last year. Margins were impacted due to lower utilisation and lower PC revenue share of 61.2% vs. 70% YoY. The management expects EBIT margin to be in mid-teens by FY23 led by a focus on premium products, the shutdown of the inefficient Russia plant and operating leverage. We expect sales CAGR of 12% and an average EBITM of 9% between FY21-23E led by the addition of a major OC client (sales started from 2H), improved client base in the PC category and wallet share gains.

Exhibit 1: Quarterly financial statement

Particulars (Rs mn)	1QFY22	1QFY21	YoY	4QFY21	QoQ
Net Sales	7,991	7,415	8%	8,102	-1%
Add: Interest income	-	23	-	-	-
Add: Other Income (OI)	53	28	87%	30	77%
Total Income	8,044	7,466	8%	8,132	-1%
Cost of material	3,371	3,139	7%	3,496	-4%
Employees cost	1,557	1,486	5%	1,576	-1%
Other expenses	1,614	1,324	22%	1,632	-1%
Total Expenditure	6,542	5,949	10%	6,704	-2%
EBITDA	1,502	1,518	-1%	1,428	5%
EBITDA (Excl. OI)	1,449	1,466	-1%	1,398	4%
Depreciation	619	579	7%	601	3%
EBIT	883	939	-6%	827	7%
Interest cost	89	163	-45%	86	3%
EBT	794	776	2%	741	7%
Tax	189	159	19%	155	22%
Tax Rate %	24%	20%		21%	
Reported PAT	605	617	-2%	586	3%
Adjusted PAT	579	444	30%	568	2%
EPS (Rs.)	1.83	1.41	30%	1.80	2%
Gross Margin	57.8%	57.7%	15 bps	56.9%	96 bps
EBITDA margin (excl. OI)	18.1%	19.8%	-164 bps	17.3%	88 bps
PAT margin	7.2%	6.0%	125 bps	7.0%	24 bps

Source: Company, Systematix Institutional Research

Exhibit 2: Geography-wise revenues

Segment Revenue	1QFY22	1QFY21	YoY	4QFY21	QoQ
AMESA	2,819	2,190	29%	2,766	2%
EAP	2,060	2,021	2%	1,849	11%
Americas	1,639	1,510	9%	1,749	-6%
Europe	1,784	1,977	-10%	2,002	-11%
<i>Unallocated</i>	<i>3</i>	<i>3</i>	<i>11%</i>	<i>3</i>	<i>0%</i>
Total sales	8,305	7,700	8%	8,369	-1%
<i>Less: Inter segment Revenue</i>	<i>-314</i>	<i>-285</i>	<i>10%</i>	<i>-267</i>	<i>18%</i>
Net Sales	7,991	7,415	8%	8,102	-1%
Revenue share:					
AMESA	34%	28%		33%	
EAP	25%	26%		22%	
Americas	20%	20%		21%	
Europe	21%	26%		24%	
<i>Unallocated</i>	<i>0%</i>	<i>0%</i>		<i>0%</i>	
EBIT:					
AMESA	311	160	95%	224	39%
EAP	345	438	-21%	216	60%
Americas	119	155	-23%	202	-41%
Europe	99	179	-45%	189	-48%
<i>Unallocated</i>	<i>-7</i>	<i>-6</i>	<i>21%</i>	<i>-9</i>	<i>-22%</i>
<i>Less: Inter segment</i>	<i>-37</i>	<i>-38</i>	<i>-2%</i>	<i>-7</i>	<i>429%</i>
EBIT Margin					
AMESA	11.0%	7.3%	374 bps	8.1%	293 bps
EAP	16.7%	21.7%	-492 bps	11.7%	507 bps
Americas	7.3%	10.2%	-297 bps	11.5%	-429 bps
Europe	5.5%	9.0%	-350 bps	9.4%	-389 bps

Source: Company, Systematix Institutional Research

Exhibit 3: Change in estimates

Particulars (Rs mn)	Revised estimates		Previous estimates		%change	
	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Sales	36,444	41,002	36,444	41,002	0%	0%
EBITDA	7,318	8,948	7,318	8,948	0%	0%
PAT	3,501	4,714	3,501	4,714	0%	0%
EPS (Rs)	11.1	14.9	11.1	14.9	0%	0%
EBITDA margin	20.1%	21.8%	20.1%	21.8%	bps	bps
PAT margin	9.6%	11.5%	9.6%	11.5%	bps	bps

Source: Company, Systematix Institutional Research

FINANCIALS (CONSOLIDATED)

Profit & Loss Statement

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Net revenues	27,069	27,601	30,916	36,444	41,002
Revenue growth (%)	11.7	2.0	12.0	17.9	12.5
- Op. expenses	22,078	22,026	24,805	29,126	32,053
EBITDA (Excl. OI)	4,991	5,574	6,111	7,318	8,948
EBITDA margins (%)	18.4	20.2	19.8	20.1	21.8
- Interest expenses	613	557	429	303	168
- Depreciation	1,861	2,298	2,346	2,629	2,821
+ Other income	285	134	145	364	410
- Tax	932	638	868	1,188	1,592
Effective tax rate (%)	33	22	25	25	25
Reported PAT	1,870	2,216	2,613	3,563	4,777
+/- Extraordinary items	-53	100	170	10	11
+/- Minority interest	-31	43	52	52	52
Adjusted PAT	1,954	2,073	2,391	3,501	4,714
EPS	6.2	6.6	7.6	11.1	14.9

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Share capital	630	631	631	631	631
Reserves & Surplus	13,248	14,695	16,350	18,180	20,624
Networth	13,879	15,326	16,981	18,811	21,255
Minority interest	52	86	333	333	333
Total Debt	7,926	9,018	7,178	4,265	2,091
Def. tax liab. (net)	510	475	543	543	543
Capital employed	22,366	24,906	25,035	23,953	24,221
Net Fixed assets	13,486	14,034	15,585	14,956	14,135
Investments	168	160	149	149	149
Net Working capital	7,368	7,000	6,887	7,820	8,796
Cash and bank balance	1,344	3,712	2,414	1,027	1,141
Capital deployed	22,366	24,906	25,035	23,953	24,221
Net debt	6,582	5,306	4,764	3,238	950
WC (days)	86	85	68	66	66
DE (x)	0.57	0.59	0.41	0.22	0.10

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
PAT	1,954	2,073	2,391	3,501	4,714
+ Non cash items	2,068	2,264	2,414	2,629	2,821
Cash profit	4,022	4,336	4,805	6,130	7,535
- Incr/(Decr) in WC	1,301	-368	-113	933	976
Operating cash flow	2,721	4,705	4,917	5,197	6,558
- Capex	3,089	2,846	3,897	2,000	2,000
Free cash flow	-368	1,858	1,021	3,197	4,558
- Dividend	394	1,041	1,293	1,733	2,333
+ Equity raised	316	0	0	-	-
+ Debt raised	585	1,093	-1,840	-2,913	-2,175
- Investments	37	-8	-11	-	-
- Misc. items	494	-450	-804	-62	-63
Net cash flow	-392	2,368	-1,298	-1,387	113
+ Opening cash	1,736	1,344	3,712	2,414	1,027
Closing cash	1,344	3,712	2,414	1,027	1,141

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY19	FY20	FY21	FY22E	FY23E
P/E (x)	21.9	18.5	32.5	21.4	16.0
P/BV (x)	3.0	2.7	5.0	4.1	3.6
EV/EBITDA (x)	9.5	8.3	14.7	10.8	8.6
RoE (%)	14.8	14.2	14.8	19.6	23.5
RoCE (%)	16.1	14.5	15.8	20.9	27.5
Fixed Asset turnover (x)	1.3	1.2	1.1	1.2	1.3
Dividend (%)	62	165	205	275	370
Dividend yield (%)	1.0	2.5	1.5	2.3	3.1
Dividend payout (%)	21	47	49	49	49
Debtors days	67	65	70	65	65
Creditor days	34	41	62	60	60
Inventory days	53	61	61	61	61
Revenue growth (%)	12	2	12	18	13
EBITDA growth (%)	9	12	10	20	22
PAT growth (%)	13	6	15	46	35

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
Navin Roy Vallabhaneni	President & Head – IE & ECM	+91-22-6704 8065	navin@systematixgroup.in
Equity Research			
Analysts	Industry Sectors	Desk-Phone	E-mail
Rahul Jain	Metals & Mining	+91-22-6704 8066	rahuljain@systematixgroup.in
Ronak Sarda	Auto, Auto Ancillaries	+91-22-6704 8059	ronaksarda@systematixgroup.in
Rakesh Kumar	Banking, Insurance	+91-22-6704 8041	rakeshkumar@systematixgroup.in
Praful Bohra	Pharmaceuticals and Healthcare	+91-22-6704 8064	prafulbohra@systematixgroup.in
Shubhranshu Mishra	NBFCs & Diversified Financials	+91-22-6704 8024	shubhranshumishra@systematixgroup.in
Sanjeev Kumar Singh	Cement, Building Materials, Paints	+91-22-6704 8017	sanjeevsingh@systematixgroup.in
Premal Kamdar	Consumer Staples	+91-22-6704 8090	premalkamdar@systematixgroup.in
Amar Kedia	Infra, Cap Goods, Logistics, Consumer Durables	+91-22-6704 8084	amarkeadia@systematixgroup.in
Ashutosh Joytiraditya	Consumer, Retail	+91-22-6704 8068	ashutoshj@systematixgroup.in
Naushad Chaudhary	Chemicals, Textiles, Building Materials, Midcaps	+91-22-6704 8036	naushadchaudhary@systematixgroup.in
Harsh Mittal	Cement, Building Materials, Paints	+91-22-6704 8098	harshmittal@systematixgroup.in
Poorvi Banka	Auto, Auto Ancillaries	+91-22-6704 8063	poorvibanka@systematixgroup.in
Nikhil Shah	Banking, Insurance	+91-22-6704 8091	nikhilshah@systematixgroup.in
Tausif Shaikh	Pharmaceuticals and Healthcare	+91-22-6704 8046	tausifshaikh@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Shilpashree Venkatesh	Macro-Strategy	+91-22-6704 8078	shilpav@systematixgroup.in
Equity Sales & Trading			
Name		Desk-Phone	E-mail
Vipul Sanghvi	Director and Head - Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Ashok Kumar Agarwal	Sales	+91-22-6704 8058	ashokagarwal@systematixgroup.in
Jigar Kamdar	Sales	+91-22-6704 8060	jigarkamdar@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8033	rahul@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Rahul Thakar	Sales Trading - Derivatives	+91-22-6704 8073	rahulthakar@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8050	vipulchheda@systematixgroup.in
Amit Sawant	Dealer	+91-22-6704 8054	amitsawant@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Suketu Vyas	Dealer	+91-22-6704 8050	suketuvyas@systematixgroup.in
Corporate Access			
Audrey Leolyn Mendonca	Assistant Vice President	+91-22-6704 8088	audreymendonca@systematixgroup.in
Production			
Yukti Vidyarthi	Editor	+91-22-6704 8071	yukti@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in
Operations			
Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Sugandha Rane	Assistant Vice President	+91-22-6704 8056	sugandha@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Ravikiran Dasaka	Manager	+91-22-6704 8622	ravikiran@systematixgroup.in
Ravi Agarwal	Assistant Manager	+91-22-6704 8016	raviagarwal@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Naushad Chaudhary**, hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSL through this presentation.

SSSL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
 CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 34600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | Investment Advisor SEBI Reg. No. INA000010414 | AMFI : ARN - 64917